MIB-626: meta-analysis of COVID-19 studies

All studies   Mortality   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -156% 1 39 Improvement, Studies, Patients Relative Risk Mortality -156% 1 39 RCTs -156% 1 39 Late -156% 1 39 MIB-626 for COVID-19 c19early.org December 2025 FavorsMIB-626 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] death 1/25 0/14 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Late treatment -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk All studies -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk 1 MIB-626 COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Effect extraction pre-specified(most serious outcome) Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] 1/25 0/14 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Late treatment -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk All studies -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk 1 MIB-626 COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) 18% 0.82 [0.29-2.27] no recov. 19 (n) 15 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.71 Late treatment 18% 0.82 [0.29-2.27] 19 (n) 15 (n) 18% lower risk All studies 18% 0.82 [0.29-2.27] 19 (n) 15 (n) 18% lower risk 1 MIB-626 COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.71 Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] death 1/25 0/14 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Late treatment -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk All studies -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk 1 MIB-626 COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Effect extraction pre-specified(most serious outcome) Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] 1/25 0/14 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Late treatment -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk All studies -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk 1 MIB-626 COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] death 1/25 0/14 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Late treatment -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk All studies -156% 2.56 [0.11-59.0] 1/25 0/14 156% higher risk 1 MIB-626 COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.57 Effect extraction pre-specified(most serious outcome) Favors MIB-626 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Pencina (DB RCT) -156% 2.56 [0.11-59.0] death 1/25 0/14 Improvement, RR [CI] Treatment Control Pencina (DB RCT) 18% 0.82 [0.29-2.27] no recov. 19 (n) 15 (n) Pencina (DB RCT) -50% 1.50 [0.08-28.5] no recov. 14 (n) 14 (n) MIB-626 COVID-19 outcomes c19early.org December 2025 Favors MIB-626 Favors control